New Cholesterol Fighters To Take Center Stage At ACC
In recent decades, high cholesterol has been Big Pharma’s gravy train. The statins, oral drugs that lower “bad” cholesterol, turned into the best-selling drugs in history, with Pfizer’s Lipitor peaking at nearly $14 billion in 2006 sales. Now, however, all the statins have gone off-patent or are about to. So Pfizer (PFE) and a passel of other companies — led by Amgen (AMGN), Regeneron (REGN) and Regeneron’s partner Sanofi (SNY) — are turning to a